Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
January 31, 2026
Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration
Márk Kerestély, István Narozsny, Levente Szarka, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 30, 2025
Cancer drug resistance as learning of signaling networks
Dávid Keresztes, Márk Kerestély, Levente Szarka, et al.
Orvosi Hetilap
|
May 5, 2020
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
Tibor Szarvas, Anita Csizmarik, Nikolett Nagy, et al.
British Journal of Pharmacology
|
February 5, 2025
System level network data and models attack cancer drug resistance
Márk Kerestély, Dávid Keresztes, Levente Szarka, et al.
Cellular and Molecular Life Sciences : CMLS
|
February 19, 2024
Cellular forgetting, desensitisation, stress and ageing in signalling networks. When do cells refuse to learn more?
Tamás Veres, Márk Kerestély, Borbála M Kovács, et al.
Urologic Oncology
|
April 10, 2018
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
BJU International
|
May 27, 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
International Journal of Cancer
|
June 11, 2022
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
Anita Csizmarik, Dávid Keresztes, Nikolett Nagy, et al.
Prostate Cancer and Prostatic Diseases
|
August 26, 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer
Anita Csizmarik, Nikolett Nagy, Dávid Keresztes, et al.
Journal of Cellular and Molecular Medicine
|
December 31, 2021
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer
Dávid Keresztes, Anita Csizmarik, Nikolett Nagy, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
January 31, 2026
Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration
Márk Kerestély, István Narozsny, Levente Szarka, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
January 30, 2025
Cancer drug resistance as learning of signaling networks
Dávid Keresztes, Márk Kerestély, Levente Szarka, et al.
Orvosi Hetilap
|
May 5, 2020
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
Tibor Szarvas, Anita Csizmarik, Nikolett Nagy, et al.
British Journal of Pharmacology
|
February 5, 2025
System level network data and models attack cancer drug resistance
Márk Kerestély, Dávid Keresztes, Levente Szarka, et al.
Cellular and Molecular Life Sciences : CMLS
|
February 19, 2024
Cellular forgetting, desensitisation, stress and ageing in signalling networks. When do cells refuse to learn more?
Tamás Veres, Márk Kerestély, Borbála M Kovács, et al.
Urologic Oncology
|
April 10, 2018
Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
BJU International
|
May 27, 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer
Tibor Szarvas, Sabina Sevcenco, Orsolya Módos, et al.
International Journal of Cancer
|
June 11, 2022
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer
Anita Csizmarik, Dávid Keresztes, Nikolett Nagy, et al.
Prostate Cancer and Prostatic Diseases
|
August 26, 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer
Anita Csizmarik, Nikolett Nagy, Dávid Keresztes, et al.
Journal of Cellular and Molecular Medicine
|
December 31, 2021
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer
Dávid Keresztes, Anita Csizmarik, Nikolett Nagy, et al.
Page
of 1